Chilton Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Chilton Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-167	Closed	-$16K	–	242
2022 Q2	$16K	Buy	+167	New	+$15.7K	﹤0.01%	414
2022 Q1	–	Sell	-167	Closed	-$22K	–	252
2021 Q4	$22K	Buy	+167	New	+$24.8K	﹤0.01%	404

Other funds holding ASND

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Chilton Capital Management's ASND Position: Q3 2022 in Review

Chilton Capital Management sold out of Ascendis Pharma A/S (ASND) in Q3 2022, closing a stake of 167 shares — an estimated $16K sold.

Chilton Capital Management first reported a position in ASND in Q4 2021 and held it in 2 quarters. The position peaked at $22K in Q4 2021. 183 funds tracked by Wall St. Rank hold ASND as of Q3 2022.

Chilton Capital Management reported no remaining Ascendis Pharma A/S position as of Q3 2022 after selling out during the quarter.
Chilton Capital Management sold 167 Ascendis Pharma A/S shares in Q3 2022, an estimated $16K.
Chilton Capital Management first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 2 quarters.
Chilton Capital Management's Ascendis Pharma A/S position peaked at $22K in Q4 2021.
183 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2022.

Based on Chilton Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.